PRCT Procept Total Debt to Capital

The market value dynamics of PROCEPT BioRobotics (PRCT) are presented below against the backdrop of robotic surgery expansion in Europe and the US, where demand for minimally invasive treatments continues to grow. The current figure is 0.23. PROCEPT BioRobotics generates revenue from the sale of prostate surgery systems and ancillary consumables. Meanwhile, the firm minimizes outsourcing, keeping calibration and assembly in-house to ensure quality.

To minimize credit risks, it is essential for an investor to evaluate the stability of the issuer's balance sheet structure. This debt-to-equity ratio is calculated as total liabilities divided by equity, determining the degree of financial leverage. For PROCEPT BioRobotics (PRCT), this is critical: the aggressive deployment of Aquabeam systems and global scaling require a balance between external financing and capital to sustain expansion.